CTOs on the Move

Exonics Therapeutics

www.exonicstx.com

 
Exonics Therapeutics was launched in February 2017 to advance the research of our scientific founder, Dr. Eric Olson and his laboratory at the University of Texas Southwestern Medical Center (UTSW) to develop treatments for patients with neuromuscular diseases. Dr. Olson is one of the world’s leading experts in the study of muscle cells and the application of gene editing to treat these types of diseases. In particular, Dr. Olson’s laboratory has used adeno-associated virus (AAV) to deliver a CRISPR/Cas9 technology that can identify and repair exon mutations to restore the production of dystrophin, a protein that helps stabilize and protect ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Exonics Therapeutics raised $40M on 11/08/2017

Similar Companies

Shenandoah Biotechnology

Shenandoah Biotechnology is a Warminster, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Soundbite Medical Solutions

SoundBite Medical is a medical devices company that began operations in May 2015, with its R&D facilities in Sherbrooke and commercialization headquarters in Montreal, Quebec. The Company is developing and commercializing proprietary wire-based device and generator console that delivers safe shockwave energy within the cardiovascular system to treat chronic total occlusions.

Ms Sarah's Creations Of Beauty

Ms Sarah's Creations Of Beauty is a Daly City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Affinia Therapeutics

We are working to methodically engineer durable gene therapies for people with devastating diseases.

Zymergen

Founded in 2013 and based in the San Francisco Bay Area, Zymergen integrates automation, machine learning, and genomics to rapidly accelerate the pace of scientific advancement. We treat the genome as a search space, leveraging machine learning to make discoveries far beyond the bounds of human intuition. In doing so, we deliver economic value, material diversity and performance capabilities not previously possible.